标题
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
作者
关键词
-
出版物
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-07-16
DOI
10.1111/cei.13495
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
- (2020) Katja Akgün et al. Frontiers in Immunology
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
- (2020) Sara Monti et al. ANNALS OF THE RHEUMATIC DISEASES
- Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study
- (2020) Carlo Salvarani et al. ANNALS OF THE RHEUMATIC DISEASES
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
- (2020) Milena Gianfrancesco et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 infection and rheumatoid arthritis: Faraway, so close!
- (2020) Ennio Giulio Favalli et al. AUTOIMMUNITY REVIEWS
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Antibody Detection and Dynamic Characteristics in Patients with COVID-19
- (2020) Fei Xiang et al. CLINICAL INFECTIOUS DISEASES
- Herd Immunity: Understanding COVID-19
- (2020) Haley E. Randolph et al. IMMUNITY
- A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
- (2020) Isabella Quinti et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment with convalescent plasma for COVID-19 patients in Wuhan, China
- (2020) Mingxiang Ye et al. JOURNAL OF MEDICAL VIROLOGY
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
- (2020) Feng-Cai Zhu et al. LANCET
- A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- (2020) Edward Fox et al. Multiple Sclerosis Journal
- COVID ‐19 in patients with myasthenia gravis
- (2020) Pria Anand et al. MUSCLE & NERVE
- The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
- (2020) Linlin Bao et al. NATURE
- The COVID-19 vaccine development landscape
- (2020) Tung Thanh Le et al. NATURE REVIEWS DRUG DISCOVERY
- Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic
- (2020) Wallace Brownlee et al. NEUROLOGY
- Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
- (2020) Maximilian Ackermann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques
- (2020) Abishek Chandrashekar et al. SCIENCE
- Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases
- (2020) Cynthia Magro et al. Translational Research
- The COVID-19 pandemic and the use of MS disease-modifying therapies
- (2020) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- COVID-19 and MS disease-modifying therapies
- (2020) Joseph R. Berger et al. Neurology-Neuroimmunology & Neuroinflammation
- Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis
- (2020) Brandon Michael Henry et al. CLINICA CHIMICA ACTA
- The possible of immunotherapy for COVID-19: A systematic review
- (2020) Akram AminJafari et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Two hits to the renin‐angiotensin system may play a key role in severe COVID ‐19
- (2020) Yu‐Hsin Tseng et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- An Italian programme for COVID-19 infection in multiple sclerosis
- (2020) Maria Pia Sormani LANCET NEUROLOGY
- Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
- (2020) C. Louapre et al. REVUE NEUROLOGIQUE
- Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
- (2020) Kulachanya Suwanwongse et al. Multiple Sclerosis and Related Disorders
- The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
- (2020) David Baker et al. Multiple Sclerosis and Related Disorders
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
- (2020) Farinaz Safavi et al. Multiple Sclerosis and Related Disorders
- BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
- (2020) E. Signoriello et al. Multiple Sclerosis and Related Disorders
- Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
- (2020) Mahsa Ghajarzadeh et al. Multiple Sclerosis and Related Disorders
- Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
- (2020) Paloma Montero-Escribano et al. Multiple Sclerosis and Related Disorders
- COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
- (2020) Giovanni Novi et al. Multiple Sclerosis and Related Disorders
- COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
- (2020) Virginia Meca-Lallana et al. Multiple Sclerosis and Related Disorders
- Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
- (2020) William L Conte Multiple Sclerosis and Related Disorders
- Characteristics of COVID-19 disease in multiple sclerosis patients
- (2020) Mahdi Barzegar et al. Multiple Sclerosis and Related Disorders
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis
- (2019) Giancarlo Comi et al. Multiple Sclerosis and Related Disorders
- Potential mechanisms of action related to the efficacy and safety of cladribine
- (2019) David Baker et al. Multiple Sclerosis and Related Disorders
- Rituximab treatment for multiple sclerosis
- (2019) Benjamin V Ineichen et al. Multiple Sclerosis Journal
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity
- (2019) Alexander Juto et al. Multiple Sclerosis and Related Disorders
- The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
- (2018) Robert Hermann et al. CLINICAL PHARMACOKINETICS
- Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
- (2018) Amit Bar-Or et al. NEUROLOGY
- B-Cell Therapies in Multiple Sclerosis
- (2018) Joseph J. Sabatino et al. Cold Spring Harbor Perspectives in Medicine
- Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis
- (2018) David Baker et al. BRAIN
- Clinical Pharmacology of Alemtuzumab, an Anti-CD52 Immunomodulator, in Multiple Sclerosis
- (2018) Zhaoyang Li et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis
- (2018) Tamara H Ramwadhdoebe et al. RHEUMATOLOGY
- Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- (2018) Stefan Gingele et al. Cells
- Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
- (2017) Janie Parrino et al. VACCINE
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
- (2017) David Baker et al. EBioMedicine
- Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection
- (2016) Oi-Wing Ng et al. VACCINE
- Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study
- (2015) A.-P. Trouvin et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients
- (2014) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection
- (2014) R. Channappanavar et al. JOURNAL OF VIROLOGY
- The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
- (2013) I. Nazi et al. BLOOD
- Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab
- (2013) W. Kim et al. EUROPEAN JOURNAL OF NEUROLOGY
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Novel CD20 monoclonal antibodies for lymphoma therapy
- (2012) Shundong Cang et al. Journal of Hematology & Oncology
- Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
- (2011) Su-Hyun Kim ARCHIVES OF NEUROLOGY
- Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine
- (2010) Sander van Assen et al. CLINICAL IMMUNOLOGY
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial
- (2009) Clifton O. Bingham et al. ARTHRITIS AND RHEUMATISM
- Rituximab-Induced Changes in Hematolymphoid Tissues Found at Autopsy
- (2008) Adina M. Cioc et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started